Epithelial-Mesenchymal Transition in Atopy: A Mini-Review.

Front Allergy

Epithelial Therapeutics Unit, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, United States.

Published: December 2020


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Atopic diseases, particularly atopic dermatitis (AD), asthma, and allergic rhinitis (AR) share a common pathogenesis of inflammation and barrier dysfunction. Epithelial to mesenchymal transition (EMT) is a process where epithelial cells take on a migratory mesenchymal phenotype and is essential for normal tissue repair and signal through multiple inflammatory pathways. However, while links between EMT and both asthma and AR have been demonstrated, as we outline in this mini-review, the literature investigating AD and EMT is far less well-elucidated. Furthermore, current studies on EMT and atopy are mostly animal models or studies on cell cultures or tissue biopsies. The literature covered in this mini-review on EMT-related barrier dysfunction as a contributor to AD as well as the related (perhaps resultant) atopic diseases indicates a potential for therapeutic targeting and carry treatment implications for topical steroid use and environmental exposure assessments. Further research, particularly studies, may greatly advance the field and translate into benefit for patients and families.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8301597PMC
http://dx.doi.org/10.3389/falgy.2020.628381DOI Listing

Publication Analysis

Top Keywords

atopic diseases
8
barrier dysfunction
8
epithelial-mesenchymal transition
4
transition atopy
4
atopy mini-review
4
mini-review atopic
4
diseases atopic
4
atopic dermatitis
4
dermatitis asthma
4
asthma allergic
4

Similar Publications

Objectives: The aim of this study is to evaluate the potential of online consultation services in a Swiss dermatological clinic as a tool for triage, focusing on time savings, patient satisfaction, and cost-effectiveness.

Methods: Over a period of 30 months, data were generated from a publicly available store-and-forward teledermatological platform (www.derma2go.

View Article and Find Full Text PDF

Background And Objectives: Pollen-food allergy syndrome (PFAS) is a frequent comorbidity in individuals with hay fever. Identifying risk factors and allergen clusters can aid targeted interventions and management strategies. Objective: This study characterizes PFAS in patients with hay fever and identifies associated risk factors using the mobile health platform, AllerSearch.

View Article and Find Full Text PDF

Microenvironment-Driven Mast Cell Plasticity: Insights From Cytokine-Activated Gene Signatures in Skin and Respiratory Diseases.

Allergy

September 2025

Department of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, Lydia Becker Institute of Immunology and Inflammation, The University of Manchester, Manchester, UK.

Mast cells (MCs) rapidly adapt to the microenvironment due to the plethora of cytokine receptors expressed. Understanding microenvironment-primed immune responses is essential to elucidate the phenotypic/functional changes MCs undergo, and thus understand their contribution to diseases and predict the most effective therapeutic strategies. We exposed primary human MCs to cytokines mimicking a T1/pro-inflammatory (IFNγ), T2/allergic (IL-4 + IL-13), alarmin-rich (IL-33) and pro-fibrotic/pro-tolerogenic (TGFβ) microenvironment.

View Article and Find Full Text PDF

Prurigo nodularis (PN) is a chronic skin inflammatory condition characterized by severe, persistent itching and excoriated nodules induced by scratching. PN is strongly related to neural and immune dysfunction and negatively impacts quality of life. Treatments for PN are often off-label, highlighting the need for specifically approved agents and consensus guidelines for patient management.

View Article and Find Full Text PDF

Background: Proper identification and management of flare in atopic dermatitis (AD) is complex, especially in patients being treated with biological drug or small molecules. To date, the definition of flare is not agreed upon. Available scores such as the ADCT (AD control tool) are administered retrospectively to the patient and do not cover key aspects such as self-medication with topical steroids.

View Article and Find Full Text PDF